Alpha 2.0
Login Register
» Articles » PMID: 40011373

Efficacy and Safety of IGlarLixi Versus Insulin Glargine in Type 2 Diabetes: a Meta-analysis of Randomized Controlled Trials

Overview
Journal Endocrine
Specialty Endocrinology
Date 2025 Feb 26
PMID 40011373
Authors
Jingxin Li
Xiaomin Wang
Jingcheng Wu
Dandan Geng
Fan Li
Yang Liu
Yanhong Shen
Affiliations
Soon will be listed here.
Abstract

Objective: This meta-analysis aimed to compare the efficacy and safety of iGlarLixi with those of insulin glargine for treating type 2 diabetes (T2D).

Methods: A systematic search of PubMed, the Cochrane Library, and EMBASE was conducted to identify randomized controlled trials (RCTs) that compared the use of iGlarLixi with the use of insulin glargine in patients with T2D. The meta-analysis protocol was registered at PROSPERO. The primary outcomes of interest were changes in hemoglobin A1c (HbA1c) and body weight. Risk ratios and mean differences with 95% confidence intervals were calculated using random-effects models.

Results: We included 7 RCTs comprising 2229 men and 1926 women, of whom 2075 (49.94%) were randomized to iGlarLixi. Compared with insulin glargine, iGlarLixi decreased HbA1c (MD: -0.50%; 95% CI: -0.65% to -0.35%; p < 0.00001) and body weight (MD: -1.17 kg; 95% CI: -1.36 kg to -0.98 kg; p < 0.00001) and self-measured plasma glucose (MD: -0.97 mmol/L; 95% CI: -1.27 mmol/L to -0.68 mmol/L; p < 0.00001) and increased the percentage of patients achieving HbA1c < 7% (RR: 1.66; 95% CI: 1.31 to 2.11; p < 0.0001), the percentage of patients achieving HbA1c < 6.5% (RR: 2.11; 95% CI: 1.53 to 2.92; p < 0.00001), and HbA1c < 7.0% without weight gain and/or without severe or blood glucose-confirmed hypoglycemic episodes (RR: 2.18; 95% CI: 1.76 to 2.69; p < 0.00001). However, a higher incidence of gastrointestinal adverse events (RR: 2.02; 95% CI: 1.61 to 2.54; p < 0.00001) and adverse events (RR: 1.08; 95% CI: 1.02 to 1.14; p = 0.008) was associated with iGlarLixi than with insulin glargine.

Conclusions: Compared with insulin glargine, iGlarLixi is superior in reducing blood glucose levels and facilitating weight loss. Nevertheless, its administration is also linked to a heightened occurrence of gastrointestinal and adverse events.

References
1.
Aroda V . A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab. 2018; 20 Suppl 1:22-33. DOI: 10.1111/dom.13162. View
2.
Rosenstock J, Diamant M, Aroda V, Silvestre L, Souhami E, Zhou T . Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. Diabetes Care. 2016; 39(9):1579-86. PMC: 5001145. DOI: 10.2337/dc16-0046. View
3.
Yuan X, Guo X, Zhang J, Dong X, Lu Y, Pang W . Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN.... Diabetes Obes Metab. 2022; 24(11):2182-2191. PMC: 9795930. DOI: 10.1111/dom.14803. View
4.
Yang W, Dong X, Li Q, Cheng Z, Yuan G, Liu M . Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial. Diabetes Obes Metab. 2022; 24(8):1522-1533. DOI: 10.1111/dom.14722. View
5.
Bajaj H, Chu L, Bansal N, Brown R, Dhillon G, Gupta R . Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial. Can J Diabetes. 2022; 46(5):495-502. DOI: 10.1016/j.jcjd.2022.02.003. View